Sells the only FDA-approved drug for recurrent pericarditis, a heart inflammation condition affecting roughly 38,000 people in the U.S.
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 0
Sells the only FDA-approved drug for recurrent pericarditis, a heart inflammation condition affecting roughly 38,000 people in the U.S.
What this company is and how it runs — written from structure, not news.
Kiniksa Pharmaceuticals sells ARCALYST, the only drug the FDA has approved for recurrent pericarditis, a heart-lining inflammation that affects roughly 38,000 diagnosed patients in the United States. Because the FDA granted ARCALYST orphan drug exclusivity specifically for that indication, any competitor wanting to enter the same approved space must first run its own clinical trials and survive a separate FDA review — not just build a manufacturing line — which keeps cardiologists with exactly one approved option to prescribe. Once a patient's symptoms stabilize on ARCALYST, insurers' prior-authorization requirements create an additional bureaucratic barrier to switching to anything else, so the revenue base tends to hold as long as patients stay on treatment. The same orphan designation that blocks competitors also caps the business: no additional manufacturing runs or sales effort can produce more than roughly 38,000 diagnosable patients, so if the FDA were ever to revoke or narrow that designation, both the competitive moat and the revenue ceiling would collapse at the same moment.
How does this company make money?
The company earns revenue each time a vial of ARCALYST is sold to specialty distributors or hospital pharmacies. The price it can charge is supported by two things: the FDA orphan drug exclusivity that prevents approved competitors, and the prior authorization rules that insurers use, which effectively lock patients into the drug once they are on it. The pipeline drugs — vixarelimab and KPL-387 — bring in no revenue yet and currently cost money to develop through ongoing clinical trials.
What makes this company hard to replace?
Before a cardiologist can even prescribe ARCALYST, insurers typically require prior authorization, which means documenting that the patient has already tried and failed on other treatments. That administrative process creates a bureaucratic barrier to switching in the first place. Once a patient's symptoms are under control on rilonacept, switching to any alternative carries real clinical risk — there is no other FDA-approved drug for this condition, so any substitute would be unproven for this use.
What limits this company?
The FDA's orphan drug designation is tied to recurrent pericarditis as a rare disease, with roughly 38,000 diagnosed cases in the U.S. That number is set by how many people get the disease, not by how much the company invests or how many vials it can produce. Once every diagnosed patient is on the drug, growth stops — no amount of extra manufacturing or marketing can create more patients.
What does this company depend on?
The company cannot operate without five things: continued FDA approval and compliance for ARCALYST's manufacturing and labeling; cell culture manufacturing facilities capable of producing the rilonacept protein; a cold-chain distribution network that holds temperatures between 2°C and 8°C end to end; Clinical Research Organization partners running trials for pipeline drugs vixarelimab and KPL-387; and active pharmaceutical ingredient suppliers for the small molecule drugs in development.
Who depends on this company?
Recurrent pericarditis patients are the most directly affected — if ARCALYST supply were cut off, they would lose the only approved treatment for their condition and risk serious cardiac complications. Clinical trial sites running Phase 2b studies for vixarelimab would lose continuity for patients already enrolled in those trials. Asia Pacific commercialization partners who have built regional distribution agreements around ARCALYST supply would also be left without product to distribute.
How does this company scale?
The biological manufacturing process — growing rilonacept in cell culture — can be expanded by using larger bioreactors and running more production batches, and those costs scale roughly in line with output. What cannot be forced to scale is patient recruitment: rare disease trials like those for recurrent pericarditis can only enroll patients as fast as those patients are diagnosed and meet the trial's entry requirements, no matter how much money is spent trying to speed it up.
What external forces can significantly affect this company?
Changes to Bermuda's corporate tax rules could affect how the company's international holding structure is taxed. FDA policy shifts on orphan drug designation — such as tightening the criteria for what counts as a rare disease or shortening the exclusivity period — could directly undermine the regulatory protection that keeps competitors out. European Medicines Agency requirements could also force changes to how global clinical trials for the pipeline drugs are designed and reviewed, adding cost and time.
Where is this company structurally vulnerable?
If the FDA changed its rules around orphan drug exclusivity — whether through a policy shift, a successful legal challenge to the recurrent pericarditis classification, or a safety-related restriction on the label — the wall keeping competitors out would come down. Every company capable of making an interleukin-1 inhibitor could then pursue the same patients at once, and the pricing power that comes from being the only approved option would disappear immediately.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Three observations have aligned: most-recent-quarter total cash is in the upper portion of its mapped range against most-recent-quarter total debt, EBITDA-to-total-liabilities is in the upper portion of its mapped range, and FCF-to-total-liabilities is in the upper portion of its mapped range.
How does this company use capital?
Three present-state observations co-occur: latest-year OCF/Net Income elevated, revenue growth composite (median × positive-year share × stability) elevated, and trailing OCF margin elevated. The configuration describes cash backing of earnings, multi-year growth consistency, and elevated cash-margin level — without claiming a causal compounding mechanism between them.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph